Table 3.
Univariate analysis of pCR and RCB class with demographics, clinical variables, and biomarkers (n = 63)
| pCR, n | pCR OR (95% CI), p value | RCB class OR (95% CI), p value | ||
|---|---|---|---|---|
| Yes (n = 30) | No (n = 33) | |||
| Median age, years | 51.8 | 52.08 | 1.00 (0.96–1.04), .09 | 0.99 (0.95–1.03), .65 |
| Race | ||||
| White | 25 | 27 | 1.00 | 1.00 |
| Other | 5 | 6 | 0.90 (0.24–3.32), .87 | 0.69 (0.19–2.57), .58 |
| Clinical stage | ||||
| 2 | 25 | 26 | 1.00 | 1.00 |
| 3 | 5 | 7 | 0.74 (0.21–2.64), .65 | 0.55 (0.16–1.82), .35 |
| Tumor grade | ||||
| Low | 1 | 1 | 1.00 | Inf (0.00–Inf), .99 |
| Intermediate | 4 | 9 | 0.45 (0.02–9.03), .60 | 1.00 a |
| High | 25 | 23 | 1.08 (0.06–18.36), .95 | 3.20 (0.90–11.37), .07 |
| TNBC molecular subtype | ||||
| BL1 | 6 | 5 | 1.00 | 1.00 |
| BL2 | 2 | 3 | 0.55 (0.07–4.76), .59 | 0.33 (0.03–3.52), .36 |
| IM | 10 | 6 | 1.39 (0.29–6.62), .68 | 0.67 (0.10–4.48), .68 |
| LAR | 2 | 5 | 3.00 (0.04–2.53), .29 | 0.17 (0.02–1.27), .10 |
| M | 5 | 10 | 0.41 (0.08–2.05), .28 | 0.19 (0.03–1.22), .08 |
| MSL | 2 | 2 | 0.84 (0.08–8.25), .88 | 0.22 (0.18–2.67), .24 |
| UNS | 3 | 2 | 1.25 (0.15–10.70), .84 | 0.33 (0.03–3.52), .36 |
| DRD status | ||||
| Wild type | 17 | 22 | 1.00 | 1.00 |
| Mutation | 11 | 3 | 4.76 (1.14–19.69), .03 | 3.75 (0.73–19.14), .11 |
| N/A | 2 | 8 | ||
| BRCA status | ||||
| Wild type | 20 | 22 | 1.00 | 1.00 |
| Mutation | 8 | 3 | 2.94 (0.68–12.55), .15 | 2.50 (0.48–13.11), .28 |
| N/A | 2 | 8 | ||
| Stromal TIL level | ||||
| Low (0%–10%) | 13 | 20 | 1.00 | 1.00 |
| Medium (11%–59%) | 13 | 9 | 2.23 (0.74–6.69), .16 | 2.22 (0.70–7.10), .18 |
| High (≥60%) | 4 | 2 | 3.06 (0.49–9.30), .23 | 1.67 (0.27–10.39), .58 |
| N/A | 0 | 2 | ||
| GSIS | ||||
| Immune‐hot | 20 | 10 | 1.00 | 1.00 |
| Immune‐cold | 10 | 23 | 4.62 (1.58–13.33), .005 | 4.80 (1.56–14.81), .01 |
a
Intermediate grade was chosen as the reference category because there was no RCB II/III with low grade.
Abbreviations: BL1, basal‐like 1; BL2, basal‐like 2; CI, confidence interval; DRD, DNA repair defect; GSIS, GeparSixto immune signature; IM, immunomodulatory; Inf, infinity; LAR, luminal androgen receptor; M, mesenchymal; MSL, mesenchymal stem‐like; N/A, not applicable; OR, odds ratio; pCR, pathological complete response; RCB, residual cancer burden; TIL, tumor‐infiltrating lymphocyte; TNBC, triple‐negative breast cancer; UNS, unspecified.